Water Advocate Kleyne Says Jury Still Out on Lacripep. Nature’s Tears® EyeMist® Still the Surest Way To Soothe Dry Eye Symptoms.
Dry eye disease is a major affliction and the process of treating it has created a 100 billion dollar business (annually). In the U.S., dry eye affects between 5% and 9% of the total population; that number increases to 35% among older women. Dry eye disease can occur due to hormonal imbalances, malfunctioning aqueous tear production or lipid production and general inflammation of the eye. Specific symptoms include redness, swelling, soreness, itching, headache and blurred vision.
Sharon Kleyne, founder of Bio-Logic Aqua® Research Water Life Science®, is a leading expert researcher and educator of the causes and relief of dry eye, and so she is paying close attention to the development and testing of a new drug. Lacripep is a topical eye drop developed by researchers at the University of Virginia Health System and was cleared for human testing in March 2017.
According to its creators, Lacripep is a topical eye drop with difference. Rather than masking dry eye symptoms, Lacripep aims to eliminate inflammatory triggers. If successful, it will do so by restoring the natural basal tearing mechanism and the health of cells. That’s not all. Lacripep may also restore the nerves on the cornea. These are the nerves that signal the brain to create more tears. Lacripep also may stabilize the eye’s tear film, which is naturally 99 percent water. In dry eye conditions, the tear film dries out from excessive evaporation.
Research specialist Gordon Laurie of the UVA School of Medicine’s Department of Cell Biology, says that “most ophthalmic drugs are washed away right away, but that’s not the case here. Lacripep is still in the tears 24 hours later because it goes into the lipid layer and apparently comes out of the lipid layer slowly to treat the eye.” According to Laurie, the root cause of the disease is a shortage of the tear protein lacritin. Lacripep is a short synthetic fragment of lacritin. If successful, Lacripep would be the first drug to treat that cause of dry eye.
“We think that dry eye disease may be much simpler than people have thought in the past, sort of like insulin and type I diabetes,” Laurie said. “With lacritin deficient in dry eye tears, topical Lacripep is a replacement therapy, which will probably not cure the disease. You would still have to keep treating your eyes, but maybe just once a day.”
Kleyne, also the host of the nationally syndicated The Sharon Kleyne Hour Power of Water, Global Climate Change and Your Health on VoiceAmerica sponsored by Nature’s Tears® EyeMist®, awaits the results of the tests with interest. Until then, she continues to urge people suffering from dry eye disease to use Nature’s Tears® EyeMist® for relief. Nature’s Tears® EyeMist® contains no chemicals and consists of 100 percent pure Trade Secret tissue culture grade water. The product is applied as a patented micron-size mist that supplements and replenishes the tear film from a personal, portable hand-held humidifier. Most eye drops trap moisture but do not replenish it.
Nature’s Tears® EyeMist® is still the dry eye solution of choice. Millions of dry eye sufferers around the world attest to that.
Were you aware of this new water technology? Have you always used eye drops in the past? What do you think of new water research and new technology? Have you ever tried Nature’s Tears® EyeMist® or known someone who has done so? What’s the verdict?
If you have comments or stories you’d like to share, why not get involved? We’d like very much to hear from you! You can reach us in the following ways. Sharon@biologicaquaresearch.com 800-367-6478 ~ Fax 541-474-2123 http://www.naturestears.com or on Twitter at @sharonkleynehr